Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026)
Viatris' (VTRS) quarterly Total Non-Current Liabilities came in at $20.1 billion in Q1 2026, down 4.22% year-on-year from $21.0 billion in Q1 2025, and down 1.82% quarter-over-quarter from $20.5 billion in Q4 2025.
Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $20.1 billion for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 4.22% year-over-year to $20.1 billion in Q1 2026; TTM through Mar 2026 was $20.1 billion, a 4.22% decrease from a year earlier, with the FY2025 full-year figure at $20.5 billion, down 2.19% from the prior year.
- Total Non-Current Liabilities fell to $20.1 billion in Q1 2026 per VTRS's latest filing, from $20.5 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $31.1 billion in Q1 2022 and bottomed at $20.1 billion in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $25.7 billion (2023), against an average of $24.7 billion.
- Across the five-year window, Total Non-Current Liabilities grew 1.28% in 2024 and fell 22.25% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $27.2 billion in 2022, then declined by 5.49% to $25.7 billion in 2023, then fell by 18.58% to $20.9 billion in 2024, then retreated by 2.19% to $20.5 billion in 2025, then retreated by 1.82% to $20.1 billion in 2026.
- Per Business Quant, the three latest VTRS Total Non-Current Liabilities figures stand at $20.1 billion (Q1 2026), $20.5 billion (Q4 2025), and $20.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 599.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 1.86 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.09 Bn |
| Dec 31, 2025 | 20.47 Bn |
| Sep 30, 2025 | 20.88 Bn |
| Jun 30, 2025 | 21.01 Bn |
| Mar 31, 2025 | 20.98 Bn |
| Dec 31, 2024 | 20.93 Bn |
| Sep 30, 2024 | 23.09 Bn |
| Jun 30, 2024 | 25.47 Bn |
| Mar 31, 2024 | 26.98 Bn |
| Dec 31, 2023 | 25.70 Bn |
| Sep 30, 2023 | 26.23 Bn |
| Jun 30, 2023 | 26.18 Bn |
| Mar 31, 2023 | 26.64 Bn |
| Dec 31, 2022 | 27.19 Bn |
| Sep 30, 2022 | 27.74 Bn |
| Jun 30, 2022 | 29.51 Bn |
| Mar 31, 2022 | 31.13 Bn |
| Sep 30, 2021 | 32.88 Bn |
| Jun 30, 2021 | 34.54 Bn |
| Mar 31, 2021 | 35.09 Bn |